Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 363


Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use.

Sewell F, Chapman K, Couch J, Dempster M, Heidel S, Loberg L, Maier C, Maclachlan TK, Todd M, van der Laan JW.

MAbs. 2017 Jul;9(5):742-755. doi: 10.1080/19420862.2017.1324376. Epub 2017 May 5.


Regulatory Forum Opinion Piece*: Use and Utility of Animal Models of Disease for Nonclinical Safety Assessment: A Pharmaceutical Industry Survey.

Morgan SJ, Couch J, Guzzie-Peck P, Keller DA, Kemper R, Otieno MA, Schulingkamp RJ, Jones TW.

Toxicol Pathol. 2017 Apr;45(3):372-380. doi: 10.1177/0192623317701004. Epub 2017 Mar 28.


Is beryllium-induced lung cancer caused only by soluble forms and high exposure levels?

Schubauer-Berigan MK, Couch JR, Deddens JA.

Occup Environ Med. 2017 Aug;74(8):601-603. doi: 10.1136/oemed-2016-104064. Epub 2017 Mar 4.


Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.

Lo M, Kim HS, Tong RK, Bainbridge TW, Vernes JM, Zhang Y, Lin YL, Chung S, Dennis MS, Zuchero YJ, Watts RJ, Couch JA, Meng YG, Atwal JK, Brezski RJ, Spiess C, Ernst JA.

J Biol Chem. 2017 Mar 3;292(9):3900-3908. doi: 10.1074/jbc.M116.767749. Epub 2017 Jan 11.


Balancing Blood Sample Volume with 3Rs: Implementation and Best Practices for Small Molecule Toxicokinetic Assessments in Rats.

Harstad E, Andaya R, Couch J, Ding X, Liang X, Liederer BM, Messick K, Nguyen T, Schweiger M, Tarrant J, Zhong S, Dean B.

ILAR J. 2016 Dec;57(2):157-165. doi: 10.1093/ilar/ilw023.


Preexisting Antibodies to an F(ab')2 Antibody Therapeutic and Novel Method for Immunogenicity Assessment.

Ruppel J, Brady A, Elliott R, Leddy C, Palencia M, Coleman D, Couch JA, Wakshull E.

J Immunol Res. 2016;2016:2921758. doi: 10.1155/2016/2921758. Epub 2016 Jun 16.


Overview of the American Society for Radiation Oncology-National Institutes of Health-American Association of Physicists in Medicine Workshop 2015: Exploring Opportunities for Radiation Oncology in the Era of Big Data.

Benedict SH, Hoffman K, Martel MK, Abernethy AP, Asher AL, Capala J, Chen RC, Chera B, Couch J, Deye J, Efstathiou JA, Ford E, Fraass BA, Gabriel PE, Huser V, Kavanagh BD, Khuntia D, Marks LB, Mayo C, McNutt T, Miller RS, Moore KL, Prior F, Roelofs E, Rosenstein BS, Sloan J, Theriault A, Vikram B.

Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):873-879. doi: 10.1016/j.ijrobp.2016.03.006. No abstract available.


Prospective Design of Anti-Transferrin Receptor Bispecific Antibodies for Optimal Delivery into the Human Brain.

Kanodia JS, Gadkar K, Bumbaca D, Zhang Y, Tong RK, Luk W, Hoyte K, Lu Y, Wildsmith KR, Couch JA, Watts RJ, Dennis MS, Ernst JA, Scearce-Levie K, Atwal JK, Ramanujan S, Joseph S.

CPT Pharmacometrics Syst Pharmacol. 2016 May;5(5):283-91. doi: 10.1002/psp4.12081. Epub 2016 May 17.


Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain.

Gadkar K, Yadav DB, Zuchero JY, Couch JA, Kanodia J, Kenrick MK, Atwal JK, Dennis MS, Prabhu S, Watts RJ, Joseph SB, Ramanujan S.

Eur J Pharm Biopharm. 2016 Apr;101:53-61. doi: 10.1016/j.ejpb.2016.01.009. Epub 2016 Jan 25.


Long-term Expectations of Vagus Nerve Stimulation: A Look at Battery Replacement and Revision Surgery.

Couch JD, Gilman AM, Doyle WK.

Neurosurgery. 2016 Jan;78(1):42-6. doi: 10.1227/NEU.0000000000000985.


Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation.

Couch JA, Zhang G, Beyer JC, de Zafra CL, Gupta P, Kamath AV, Lewin-Koh N, Tarrant J, Allamneni KP, Cain G, Yee S, Ross S, Cook R, Tsai SP, Ruppel J, Ridgway JB, Paluch M, Hass PE, Franklin J, Yan M.

Clin Cancer Res. 2016 Mar 15;22(6):1469-79. doi: 10.1158/1078-0432.CCR-15-1380. Epub 2015 Nov 20.


Treatment of headache following triptan failure after successful triptan therapy.

Lenaerts ME, Couch JR Jr.

Curr Treat Options Neurol. 2015 Jun;17(6):353. doi: 10.1007/s11940-015-0353-6.


Intractable pruritus during outpatient epidural hydromorphone infusion: a case report and a focused review of the literature.

Ruan X, Ma L, Couch JP, Chen T, Bumgarner GW.

J Opioid Manag. 2015 Mar-Apr;11(2):184-90. doi: 10.5055/jom.2015.0267. Review.


Evaluation of a multiple sclerosis cluster among nurses in an inpatient oncology ward.

Page EH, Couch JR, de Perio MA.

J Occup Environ Hyg. 2015;12(5):D54-9. doi: 10.1080/15459624.2014.989359. No abstract available.


Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.

Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M, Maloney JA, Meilandt WJ, Bumbaca D, Gadkar K, Hoyte K, Luk W, Lu Y, Ernst JA, Scearce-Levie K, Couch JA, Dennis MS, Watts RJ.

Sci Transl Med. 2014 Nov 5;6(261):261ra154. doi: 10.1126/scitranslmed.3009835.


Section Editor's Comment on the 2014 Topical Collection on Traumatic Brain Injury (TBI).

Couch JR.

Curr Treat Options Neurol. 2014 Dec;16(12):322. doi: 10.1007/s11940-014-0322-5. No abstract available.


Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials.

Sewell F, Chapman K, Baldrick P, Brewster D, Broadmeadow A, Brown P, Burns-Naas LA, Clarke J, Constan A, Couch J, Czupalla O, Danks A, DeGeorge J, de Haan L, Hettinger K, Hill M, Festag M, Jacobs A, Jacobson-Kram D, Kopytek S, Lorenz H, Moesgaard SG, Moore E, Pasanen M, Perry R, Ragan I, Robinson S, Schmitt PM, Short B, Lima BS, Smith D, Sparrow S, van Bekkum Y, Jones D.

Regul Toxicol Pharmacol. 2014 Oct;70(1):413-29. doi: 10.1016/j.yrtph.2014.07.018. Epub 2014 Jul 29.


Evaluation of exposures to healthcare personnel from cisplatin during a mock demonstration of intra-operative intraperitoneal chemotherapy administration.

Kushnir CL, Fleury AC, Couch J, Hill MC, Spirtos NM.

Gynecol Oncol. 2013 Aug;130(2):350-3. doi: 10.1016/j.ygyno.2013.04.467. Epub 2013 May 3.


Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier.

Couch JA, Yu YJ, Zhang Y, Tarrant JM, Fuji RN, Meilandt WJ, Solanoy H, Tong RK, Hoyte K, Luk W, Lu Y, Gadkar K, Prabhu S, Ordonia BA, Nguyen Q, Lin Y, Lin Z, Balazs M, Scearce-Levie K, Ernst JA, Dennis MS, Watts RJ.

Sci Transl Med. 2013 May 1;5(183):183ra57, 1-12. doi: 10.1126/scitranslmed.3005338.

Supplemental Content

Loading ...
Support Center